QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ohe, T. Articles by Ishii, Y. Search for Related Content PubMed PubMed Citation Articles by Ohe, T. Articles by Ishii, Y.

EFFECT OF P-GLYCOPROTEIN-MEDIATED EFFLUX ON CEREBROSPINAL FLUID/PLASMA CONCENTRATION RATIO

Banyu Tsukuba Research Institute, Ibaraki, Japan (T.O., M.S., S.T., N.F., M.H., Y.S., A.K., T.F., M.C., Y.I.); and Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania (M.Y.)

The ratio of drug levels in cerebrospinal fluid (CSF) to plasma (CSF/plasma) at equilibrium has been viewed as in vivo free fraction (fp) in plasma [CSF/plasma = fp], if no active transport is involved in brain penetration. We determined the CSF/plasma level following oral administration in rats and in vitro rat plasma protein binding for 20 compounds that were synthesized in our institute and have similar physicochemical properties. However, results indicated that the CSF/plasma was not only poorly correlated with fp but remarkably lower than fp in most of the compounds tested, suggesting that certain transporters such as P-glycoprotein (P-gp) located in blood-brain barrier (BBB) may decrease the unbound drug concentration in the brain. We evaluated P-gp-mediated transport activity of the 20 compounds with P-gp (mdr1a)-transfected LLC-PK1 cells and calculated P-gp efflux index (PEI), indicating the extent of P-gp-mediated transport. A plot of the CSF/plasma versus fp/PEI showed a strong correlation (r = 0.93), and the absolute values were almost identical [CSF/plasma = fp/PEI]. These results suggest that P-gp quantitatively shifts the equilibrium of unbound drugs across the BBB. Although we cannot rule out the possibility that endogenous transporters other than P-gp on BBB and/or blood-CSF barrier may affect CSF levels of compounds, the present study indicated that fp and PEI measurements may be useful in predicting in vivo CSF/plasma fractions for central nervous system-targeting drugs.

This article has been cited by other articles:

				S. Syvanen, O. Lindhe, M. Palner, B. R. Kornum, O. Rahman, B. Langstrom, G. M. Knudsen, and M. Hammarlund-Udenaes Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport Drug Metab. Dispos., March 1, 2009; 37(3): 635 - 643. [Abstract] [Full Text] [PDF]

				K. Venkatakrishnan, E. Tseng, F. R. Nelson, H. Rollema, J. L. French, I. V. Kaplan, W. E. Horner, and M. A. Gibbs Central Nervous System Pharmacokinetics of the Mdr1 P-Glycoprotein Substrate CP-615,003: Intersite Differences and Implications for Human Receptor Occupancy Projections from Cerebrospinal Fluid Exposures Drug Metab. Dispos., August 1, 2007; 35(8): 1341 - 1349. [Abstract] [Full Text] [PDF]

				S. G. Summerfield, A. J. Stevens, L. Cutler, M. del Carmen Osuna, B. Hammond, S.-P. Tang, A. Hersey, D. J. Spalding, and P. Jeffrey Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1282 - 1290. [Abstract] [Full Text] [PDF]